Objectives: To identify autoantibody signatures in ovarian cancer using protein microarray technology.
Design and methods: Protein microarrays were screened using non-malignant peritoneal fluid (n=30) and ascites fluid pooled from ovarian cancer patients (n=30).
Results: Fifteen potential tumour-associated antigens were discovered. AASDHPPT showed the strongest signal-to-noise ratio.
Conclusions: Protein microarrays are suitable for autoantibody discovery in ovarian cancer but the signatures are of low frequency.